Juan Garcia Valero
Research group
- Microenvironment in lymphoma pathogenesis and therapy Assistant researcher (R2C)
About me
Graduated in Biology (2006) and Biochemistry (2007) at the University of Barcelona. I completed my Ph.D. in Biochemistry in 2010 at the École Normale Supérieure de Lyon (France). Following my initial postdoctoral experience in the Unidad de Biofisika at UPV/EHU (Spain), I joined Fundació de Recerca Barcelona-Clinic/IDIBAPS as a junior postdoctoral researcher in 2015.
Currently, I am developing my research as a CIBERONC Researcher under the supervision of Dr. Patricia Pérez Galán, focusing on the relationship between the tumor microenvironment and B-cell Non-Hodgkin Lymphomas (B-NHL), using 2D and 3D models of tumors derived from cancer cells of patients with the aim of developing new therapies against these diseases.
Featured publications
-
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Authors:Reference: Blood Cancer Journal 2024. -
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses
Authors:Reference: Leukemia 2023. -
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Authors:Reference: Journal For Immunotherapy Of Cancer 2023. -
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
Authors:Reference: Leukemia 2021. -
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax
Authors:Reference: Blood Advances 2020. -
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Authors:Reference: Haematologica 2020. -
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
Authors:Reference: Haematologica 2019. -
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
Authors:Reference: Oncogene 2018.
Featured Projects
-
Transpyrenean network of advanced therapies in non-Hodgkin lymphoma - THERAVLINFO (INTERREG-POCTEFA program EFA123/1)
Principal investigator: Dolors Colomer Pujol, Patricia Pérez GalánDuration: 01/01/2024